Paper Details

  1. Home
  2. Paper Details

Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.

Author: ChunJerold, KiharaYasuyuki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This review summarizes the currently approved disease-modifying therapies (DMTs) for multiple sclerosis (MS) and provides details on the molecular pharmacology, immunopharmacology, and neuropharmacology of sphingosine 1-phosphate (S1P) receptor (S1PR) modulators. It highlights the CNS-oriented, astrocyte-centric mechanism of action of fingolimod, a S1PR modulator, suggesting a potential dual role in reducing both inflammation and neurodegeneration in MS.
Paper Details　
Original Abstract of the Article :
Multiple sclerosis (MS) is a neurological, immune-mediated demyelinating disease that affects people in the prime of life. Environmental, infectious, and genetic factors have been implicated in its etiology, although a definitive cause has yet to be determined. Nevertheless, multiple disease-modifyi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.pharmthera.2023.108432

データ提供：米国国立医学図書館（NLM）

S1P Receptor Modulators: Navigating the Shifting Sands of Multiple Sclerosis

Multiple sclerosis (MS) is a challenging and complex condition, like a vast and ever-changing desert landscape. This research explores the role of S1P receptor modulators, like a skilled desert navigator, in treating MS, focusing on their unique mechanisms of action and potential benefits. The study aims to review the current understanding of S1P receptor modulators, highlighting their molecular and neuroimmune pharmacology, and their potential as disease-modifying therapies for MS. The researchers found that S1P receptor modulators, like a skilled desert navigator, can effectively navigate the shifting sands of MS, influencing both the immune system and the central nervous system. This study offers valuable insights into the potential of S1P receptor modulators in treating MS and underscores the importance of exploring new approaches to manage this complex disease.

S1P Receptor Modulators: A New Compass in the Desert of Multiple Sclerosis

This study sheds light on the potential of S1P receptor modulators to effectively navigate the shifting sands of MS, offering hope for patients seeking effective treatment options. This research highlights the importance of exploring innovative approaches to manage this complex disease.

A Brighter Future for MS Patients: Navigating the Desert Landscape

The findings suggest that S1P receptor modulators could offer a valuable compass for navigating the complex desert landscape of MS, potentially improving outcomes for patients. This research represents a significant step forward in the fight against MS, offering a brighter future for those affected by this debilitating condition.

Dr.Camel's Conclusion

The desert of multiple sclerosis can be a challenging and unpredictable journey. This study offers a glimmer of hope with S1P receptor modulators, like a skilled desert navigator, that offer a new approach to managing this complex condition. This research could lead to a brighter future for MS patients, offering a path toward a more comfortable and fulfilling life.

Date :
  1. Date Completed 2023-05-29
  2. Date Revised 2023-06-01
Further Info :

Pubmed ID

37149155

DOI: Digital Object Identifier

10.1016/j.pharmthera.2023.108432

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.